Related Experiment Video
Updated: Jun 20, 2026

Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt
A Saavedra1, J M García-Martínez, X Xifró
1Departament de Biologia Cellular, Immunologia i Neurociències, Facultat de Medicina, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Casanova 143, Barcelona, Spain.
Insights
Mutant huntingtin lowers PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) levels, affecting Akt activation in Huntington's disease (HD) models. This downregulation may protect neurons by maintaining Akt activity, even after mutant huntingtin silencing.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Huntington's disease (HD) pathophysiology involves gene expression dysregulation.
- Mutant huntingtin (mHTT) is implicated in HD pathogenesis.
- PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) dephosphorylates and inactivates Akt at Ser473.
Purpose of the Study:
- To investigate the regulation of PHLPP1 by mutant huntingtin.
- To determine the impact of PHLPP1 levels on Akt activation in HD.
Main Methods:
- Analysis of PHLPP1 protein and mRNA levels in HD mouse models (knock-in and transgenic) and HD patient samples.
- Quantitative PCR to assess PHLPP1 mRNA expression.
- Western blot analysis to measure phosphorylated Akt (Ser473) levels.
- Investigation using a conditional Tet/HD94 mouse model to observe PHLPP1 and Akt levels after mHTT shutdown.
Main Results:
- Decreased PHLPP1 protein and mRNA levels were observed in the striatum of various HD models and in HD patient putamen.
- Increased phosphorylated Akt (Ser473) levels were detected in the striatum of HD models.
- In the Tet/HD94 model, PHLPP1 levels recovered to wild-type levels after mHTT shutdown, while phospho-Akt levels partially decreased.
Conclusions:
- Mutant huntingtin downregulates PHLPP1 expression.
- Reduced PHLPP1 in the striatum contributes to sustained Akt activation in HD.
- Sustained Akt activation may offer neuroprotection and promote neuronal recovery after mHTT silencing.
Abstract:
Dysregulation of gene expression is one of the mechanisms involved in the pathophysiology of Huntington's disease (HD). Here, we examined whether mutant huntingtin regulates the levels of PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1), a phosphatase that specifically dephosphorylates Akt at Ser473. Our results show decreased PHLPP1 protein levels in knock-in models (Hdh(Q111/Q111) mouse striatum and STHdh(Q111/Q111) cells), in the striatum of N-terminal exon-1 mutant huntingtin transgenic mouse models (R6/1; R6/1 : BDNF + or - , R6/2 and Tet/HD94) and in the putamen of HD patients. Quantitative PCR analysis revealed a reduction in PHLPP1 mRNA levels in the striatum of R6/1 compared with wild-type mice. Coincident with reduced PHLPP1 protein levels, we observed increased phosphorylated Akt (Ser473) levels specifically in the striatum. The analysis of the conditional mouse model Tet/HD94 disclosed that after mutant huntingtin shutdown PHLPP1 levels returned to wild-type levels whereas phospho-Akt levels were partially reduced. In conclusion, our results show that mutant huntingtin downregulates PHLPP1 expression. In the striatum, these reduced levels of PHLPP1 can contribute to maintain high levels of activated Akt that may delay cell death and allow the recovery of neuronal viability after mutant huntingtin silencing.
Related Concept Videos
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Amplifying Signals via Enzymatic Cascade
Huntington Disease l: Introduction
